Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase II Study of Pembrolizumab + Paclitaxel +/- Bevacizumab in Patients With Recurrent Triple-Negative Breast Cancer Who Received Perioperative Immunotherapy

NCT06976944 is registered in ClinicalTrials.gov with Yukinori Ozaki as lead sponsor.

NCT NCT06976944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06976944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase II Study of Pembrolizumab + Paclitaxel +/- Bevacizumab in Patients With Recurrent Triple-Negative Breast Cancer Who Received Perioperative Immunotherapy
Lead sponsor
Yukinori Ozaki
Phase
Phase 2
Overall status
Recruiting
Start date
June 24, 2025
Completion date
September 30, 2029
Enrollment
24 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent triple-negative breast cancer